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Abstract
Eleven anti-HIV Env monoclonal antibodies (MAbs) were isolated from mice immunized with soluble Env proteins derived from the clade B
Env, SF162, or ΔV2 (a derivative of SF162 lacking the V2 loop). All six anti-gp120 MAbs studied, neutralized SF162 and their activities were
dependent by the glycosylation patterns of the V1, V2 or V3 loops. Only one anti-gp120 MAb (an anti-V3 MAb) displayed cross-neutralizing
activity, which was influenced by the type of V1 loop present on the target heterologous viruses. None of the five anti-gp41 MAbs studied
displayed anti-SF162 neutralizing activity. Our studies indicate that the current limitation of soluble HIV Env gp140 immunogens to elicit robust
cross-reactive neutralizing antibody responses is not only due to the elicitation of high titers of homologous antibodies but also due to the
elicitation of antibodies whose epitopes are naturally occluded, or not present, on the virion-associated Env.
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Soluble trimeric gp140 HIV Env proteins are currently being
tested as potential immunogens to elicit broadly-reactive
neutralizing antibodies (NAbs) against primary HIV isolates
and several groups have shown that trimeric gp140 proteins are
more effective in eliciting NAbs against heterologous HIV
isolates than soluble monomeric gp120 immunogens (Barnett et
al., 2001; Beddows et al., 2005; Earl et al., 2001; Grundner et
al., 2005; Kim et al., 2005; Li et al., 2006; Yang et al., 2001).
Overall, however, the potential of the currently available
trimeric gp140 proteins to elicit broadly reactive neutralizing⁎ Corresponding author. Seattle Biomedical Research Institute, 307 Westlake
Avenue North, Seattle, WA 98109, USA. Fax: +1 206 256 7229.
E-mail address: leo.stamatatos@sbri.org (L. Stamatatos).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.05.020antibody (NAb) responses is limited in that the antibodies
elicited by such constructs can neutralize only a handful of
heterologous primary isolates (Barnett et al., 2001; Beddows
et al., 2005; Earl et al., 2001; Grundner et al., 2005; Kim et al.,
2005; Li et al., 2006; Yang et al., 2001). We believe that by
examining the immunogenic properties of gp140 constructs we
will be able to optimize their design and improve their abilities
to elicit cross-reactive NAbs.
We have been designing soluble trimeric gp140 proteins
derived from the CCR5-tropic primary clade B HIV-1 isolate
SF162, which is susceptible to neutralization by broadly
reactive NAbs, such as b12, 447-52D, 2G12, 2F5 and 4E10
(Binley et al., 2004; Saunders et al., 2005). We hypothesized
that since the epitopes recognized by these NAbs are exposed
on the SF162 Env, SF162 Env-derived gp140 constructs may
elicit such antibodies upon immunization. However, the
SF162gp140 protein elicits cross-reactive NAbs with a narrow
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second hypervariable region improves the ability of this protein
(termed ΔV2gp140) to elicit NAbs but only against certain
isolates (Barnett et al., 2001; Burke et al., 2006), but not against
others (Derby et al., 2006; Xu et al., 2006). In contrast, deletion
of the third hypervariable region from SF162gp140 (termed
ΔV3gp140) abrogates its ability to elicit cross-reactive NAbs
(Derby et al., 2006). Our initial analysis of the immunogenic
properties of SF162gp140-derived proteins indicated that the
majority of the NAbs elicited by such constructs target the first
hypervariable region (V1 loop) (Derby et al., 2006). This may
explain the narrow breadth of NAb responses elicited by these
immunogens since the V1 loop is highly variable. The above-
mentioned immunogenicity results were obtained using poly-
clonal macaque sera in peptide competition neutralization and
ELISA assays (Derby et al., 2006). Such experiments provide a
general information on the epitopes recognized by the various
types of antibodies present in the polyclonal responses to Env
immunogens, but they provide little information on how
antibodies with specific epitope specificities bind to their
targets and how the kinetics of such interactions influence the
neutralization potential of the antibodies. Such information can
be however obtained with the use of monoclonal antibodies
(MAbs) isolated from the immunized animals.
MAbs have been isolated previously by other groups from
animals immunized with oligomeric HIV Env immunogens and
their epitopes have been defined (Broder et al., 1994; Earl et al.,
1997). Here, we focused our efforts to better understand the
molecular details of the interaction of such antibodies with their
targets on the virion surface. Specifically, we investigated how
the binding properties of individual gp140-elicited antibodies,
such as their association and dissociation rates and affinity
constants, affect their neutralization potentials. We also
examined how the binding of these MAbs to their epitopes on
the virion surface is influenced by the positioning of the variable
Env regions and by the glycosylation pattern of Env.
Our results indicate that the gp41 portion of our gp140
constructs is immunogenic, but the elicited antibodies have no
neutralizing activity. The V1 loop is also highly immunogenic
on these gp140 constructs, but it elicits only homologous
neutralizing antibodies. In contrast, the V3 loop on these gp140
constructs is less immunogenic than the V1 loop but is capable
of eliciting NAbs with a narrow breadth of cross-reactivity,
limited in part due to epitope masking by the V1 region on
heterologous primary isolates. The results of this study have
implications for optimizing the presentation of conserved
neutralization epitopes on the next generation of HIV Env
gp140 vaccine constructs.
Results
Gp120 and gp41 specificity of MAbs
In this study, two Env gp140 constructs (SF162gp140 and
ΔV2gp140) and two methods of immunization (recombinant
HIV Env protein and DNA-prime followed by recombinant
protein boost) were used to elicit anti-HIV Env antibodies inmice. Eleven MAbs were cloned from hybridomas, all of which
are of either IgG1 or IgG2α with κ light chains (Table 2).
Initial screening for epitope-specificity was performed by
ELISA using the SF162gp120 and HxB2gp41 proteins as
screening agents (Fig. 1). Six MAbs were specific for gp120
while 5 were specific for gp41 (Fig. 1 and Table 2). Four of the
six anti-gp120 MAbs were derived by immunization with
ΔV2gp140 while four of the five anti-gp41 MAbs were derived
by immunization with SF162gp140 (Table 2). Four anti-gp41
MAbs were elicited by DNA prime plus recombinant protein
boost and only one was elicited by recombinant protein
immunization alone. Two anti-gp120 MAbs were elicited by
DNA prime plus recombinant protein boost and the remaining
four were elicited by recombinant protein immunization alone.
The epitopes of these 11 MAbs were further characterized by
peptide and chimeric protein ELISA (Table 1).
Epitope-specificity of the anti-gp120 MAbs
All six anti-gp120 MAbs recognized peptides derived from
the variable regions of gp120. Four MAbs (P1H6, P3B2,
P3C8 and P4D7) targeted the V1 loop, as indicated by their
recognition of the V1 ‘whole’ peptide which represents the
entire V1 loop of SF162 (Table 1). Finer mapping of these V1
epitopes using overlapping peptides derived from the
SHIVSF162P3 Env and the HIV-1 clade B consensus Env
indicated that the epitopes were all located in the central
region of the V1 loop but differed slightly from each other.
P1H6 bound to peptides 7441 (NLENATNTTSSNWKE) and
7443 (TSSNWKEMNRGEIKN), but not to any of the other
V1 peptides tested, suggesting that its minimal epitope is the
SSNWKE motif of the SF162 V1 loop. Specificity of P1H6 for
SSNWKE is consistent with its lack of reactivity with V1
peptides derived from the HIV-1 clade B consensus, which do
not contain this sequence. P3C8, P3B2, and P4D7 all bound to
just one peptide, 7444 (WKEMNRGEIKNCSFN). The inability
of these MAbs to bind to peptide 7445 (NRGEIKNCSFNVTTS)
is consistent with their inability to recognize peptides derived
from the HIV-1 clade B consensus V1, which contains GEIKNC.
Thus, the minimal epitopes of P3C8, P3B2, and P4D7 are most
likely all located within the N-terminal portion of peptide 7444,
WKEM(D/N)R.
All four anti-V1 MAbs bound to the chimeric protein
containing the V1V2 region of SF162 on the MLV background
(V1V2-CP) with greater affinity than the V1 peptides (Table 1),
suggesting that the binding of these MAbs is partially dependent
on the conformation of V1.
The presence of the V3 loop is not required for the binding
of these four anti-V1 MAbs to their epitopes even though V1
and V3 loops interact on the Env trimer (Chen et al., 2005)
since the MAbs were able to interact with an SF162gp140
protein that lacks the central region of the V3 loop
(ΔV3gp140) (Derby et al., 2006; Saunders et al., 2005)
(data not shown).
The remaining two anti-gp120 MAbs, P3E1 and P3C5, both
bound to the crown of the V3 loop (Table 1). P3E1 bound to the
SF162 V3 peptide and to the chimeric protein which expresses
Fig. 1. Recognition of Env protein antigens by MAbs. Binding of the six anti-gp120 (A) and five anti-gp41 (B) MAbs to various Env protein antigens was determined
by ELISA as described in Materials and methods. The following five Env proteins were used: trimeric SF162 gp140 (open circles), trimeric ΔV2 gp140 (filled
triangles), monomeric ΔV2 gp140 (filled circles), monomeric SF162 gp120 (filled squares), and HxB2 gp41 (open inverted triangles). Data are the average of two
independent experiments. The error bars represent standard deviations of the mean.
435N.R. Derby et al. / Virology 366 (2007) 433–445the heterologous V3 loop of the JR-CSF Env (V3-CP) (differs
from that of SF162 V3 at four amino acid positions) with a
higher (by over 2 Log10) affinity than P3C5 (Table 1).
Because P3E1 displayed cross neutralizing activity (see
below), we mapped its epitope more precisely using over-
lapping V3 peptides derived from the HIV-1 clade B consensus,
HIV-1 MN, and SHIVSF162P3 (Table 1). In parallel, we
examined the binding of the well-characterized broadly
neutralizing anti-V3 human MAb, 447-52D, to the same
peptides. The minimal epitope of 447-52D is GPGR (Zolla-
Pazner et al., 2004), and 447-52D bound only to V3 peptides
from the three isolates (cladeB consensus,MN, and SHIVSF162P3)
which contain the GPGR motif (Table 1). One exception was
noted: 447-52D did not recognize the B consensus 8840 peptide
(IGPGRAFYTTGRIIG). Like 447-52D, P3E1 recognized the
two B consensus peptides that express the GPGR motif (8838
[NNTRKSIHIGPGRAF] and 8839 [KSIHIGPGRAFYTTG])
(Table 1), and like 447-52D, P3E1 could not bind to peptide
8840 (IGPGRAFYTTGEIIG). P3E1 also recognized the MN
peptide 6286 (RKRIHIGPGRAFYTT) but, unlike 447-52D, did
not recognize peptide 6285 (NYNKRKRIHIGPGRA). These
observations suggest that the presence of a phenylalanine (F) at
the C-terminus of the GPGR motif may be important for P3E1
binding. P3E1 was incapable of recognizing the V3 peptides
spanning the same region of the SHIVSP162P3 Env which containsthe GPGK instead of the GPRG motif, suggesting that the P3E1
epitope requires the presence of arginine (R) in the GPGX motif,
like 447-52D. These results indicate that that the P3E1 epitope is
within the V3 crown sequence IGPGRAF.
In contrast to P3E1, the second anti-V3 MAb, P3C5,
recognized with low affinity only the SF162 V3 peptide and the
V3-CP, and did not bind to the heterologous or consensus V3
peptides tested here (Table 1).
We examined the binding of these anti-gp120MAbs to trimeric
SF162gp140, trimeric ΔV2gp140, monomeric ΔV2gp140, and
monomeric SF162gp120 to determine whether binding of these
MAbs to their epitopes in V1 and V3 depended on the presence
of V2 or on the oligomeric structure of the Env protein (Fig. 1A).
These anti-gp120 MAbs had similar affinities for all of the
proteins used, suggesting that their binding does not depend on
the presence of the V2 loop or on the oligomerization state of
Env.
Epitope-specificity of the anti-gp41 MAbs
Using overlapping peptides, we mapped the epitopes of two
of the five anti-gp41 MAbs to the surface-exposed C-terminal
side of the gp41 ectodomain (Table 1). This is anticipated since
the bulk of the N-terminal side of gp41 is buried within the Env
trimer (Lu et al., 1995) and is involved in gp41–gp41 contacts
Table 1
Epitope mapping using peptides and chimeric proteins
a Numbers refer to the catalog number in the NIH ARRRP for Env 15-mer peptides; ‘whole’ refers to the entier V1 loop; CP refers to a chimeric MLV antigen
expressing the V1V2 region of SF162 (V1V2-CP) or the V3 region of JR-CSF (V3-CP).
b Amino acids differing from the amino acid present in SF162 are underlined.
c ELISA half-maximal binding affinities (μg/ml) for peptides and CP are denoted by + symbols: ++++=b0.01; +++=0.01–0.1; ++=0.1–1.0; +=1.0–10.0;
+/−=N10.0; −=no binding.
d Only the V1 portion of the V1V2 insert is shown.
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1997). P1G9 recognizes an epitope in the immunodominant
cluster I region overlapping the disulfide loop. P1G9 binding
was detected to peptides 7556 (WGCSGKLICTTAVPW) and
7557 (GKLICTTAVPWNASW), suggesting that the minimal
epitope of P1G9 is likely contained within the GKLICTTAVPW
sequence, which is immediately C-terminal to the disulfide loop
and contains an immunodominant epitope (Palacios-Rodriguez
et al., 2007; Zolla-Pazner, 2004). The second anti-gp41 MAb
(P2D2) bound to peptide 7563 (NNMTWMEWEREIGNY) but
not to peptides 7561 (NKSLDQIWNNMTWME), 7562
(DQIWNNMTWMEWERE), or 7564 (WMEWEREIGNY-
TNLI), indicating that the epitope is contained within the
sequence NNMTWMEWEREREIGNY in the C-heptad repeat(C-HR) region of gp41. So far we have been unable to map the
epitopes of the remaining three anti-gp41 MAbs, P3G9, P4A3,
and P4C2 using peptides.
Interestingly, and contrary to what we observed with the anti-
gp120 MAbs, the four anti-gp41 MAbs recognized the trimeric
ΔV2gp140 protein while they did not recognize the monomeric
ΔV2gp140 protein (Fig. 1B). It appears therefore that their
epitopes are affected by the state of Env oligomerization.
Neutralizing potentials of the isolated MAbs
Neutralization of SF162
Five (P3E1, P1H6, P3C8, P4D7 and P3B2) of the six anti-
gp120 MAbs neutralized SF162 potently (IC50 between 0.2 and
437N.R. Derby et al. / Virology 366 (2007) 433–4451 μg/ml) (Table 3 and data not shown). The sixth MAb, P3C5,
neutralized SF162 with significantly reduced potency; at the
highest MAb concentration tested (25 μg/ml), 80% inhibition of
infection was not achieved. In contrast, none of the anti-gp41
MAbs neutralized SF162, suggesting that although the epitopes
of these MAbs are better exposed on the soluble trimeric gp140
Env than the soluble monomeric gp140 Env (Fig. 1B), they are
not accessible on virion-associated Env spikes.
Neutralization of ΔV2 and ΔV1 viruses
Although our binding studies with recombinant SF162gp140
andΔV2gp140 proteins indicated that the MAbs bound equally
well to these two proteins (Fig. 1), our previous neutralization
data implicated the V2 loop in preventing the neutralizing
action of certain anti-gp41 MAbs (Saunders et al., 2005). We
thus compared the abilities of the anti-gp41 MAbs to neutralize
the SF162 and ΔV2 viruses (Stamatatos and Cheng-Mayer,
1998). Although the anti-gp41 MAbs were all unable to
neutralize SF162, one MAb, P3G9, weakly neutralized ΔV2
(Table 3) (IC50=25 μg/ml). What is interesting is that this MAb
was elicited following immunization with the SF162gp140
immunogen and not the ΔV2gp140 immunogen (Table 2).
In contrast to the resistance of the ΔV2 virus to neutraliza-
tion by 4 out of 5 of the anti-gp41 MAbs tested here, the ΔV2
virus was significantly more susceptible (between 10- and 300-
fold) to neutralization by all of the anti-gp120 MAbs examined,
irrespective of their epitopes on the V1 or V3 loops (Table 3).
These results are in agreement with previous studies from our
group, which show that the ΔV2 virus is more sensitive than
SF162 to neutralization by diverse anti-gp120 MAbs (Saunders
et al., 2005).
To further examine the mechanisms of neutralization of these
MAbs, we examined their abilities to neutralize an SF162-
derived virus whose Env lacks the V1 loop (Saunders et al.,
2005). As anticipated, the anti-V1 MAbs could not neutralize
the ΔV1 virus (Table 3). In contrast, however, to what we
observed with the ΔV2 virus, the anti-V3 MAbs P3E1 and
P3C5 neutralized ΔV1 with approximately 20-fold (P3E1) and
3.5-fold (P3C5) reduced potency compared to SF162 (Table 3).
This observation suggests that the exposure and/or conforma-
tion of these V3 epitopes is affected by the positioning of the V1
loop. We were unable to detect neutralization of ΔV1 by the
anti-gp41 MAbs (Table 3). Thus, the neutralizing potentials of
the anti-V1 and anti-V3 MAbs discussed here are affected by
the presence of the V2 loop, and the neutralizing potentials of
the anti-V3 MAbs are in addition affected by the V1 loop. In
contrast, the V2 loop affected (but only marginally) the
neutralizing potential of only one anti-gp41 MAb characterized
here. Overall, the neutralizing potentials of the MAbs discussed
here are affected by the presence of the V1 and V2 loops in a
similar manner to that observed previously with human MAbs
isolated from HIV infected patients (Saunders et al., 2005).
Neutralization of ‘deglycosylated’ SF162
Certain N-linked glycans present within or at the base of the
V1, V2 and V3 loops affect the neutralization phenotype of
diverse HIV-1 clade B isolates and modulate the neutralizingpotential of NAbs (Blay et al., 2006; Losman et al., 2001; Ly
and Stamatatos, 2000; Malenbaum et al., 2000; McCaffrey et
al., 2004; Wei et al., 2003). Here we examined the role that
glycans in these regions might play in protecting the epitopes of
the newly identified anti-V1, anti-V3, and anti-gp41 MAbs
(Table 4). We compared the neutralization susceptibility of
SF162 with the susceptibilities of SF162-derived viruses which
express Envs mutated to remove specific sites for N-linked
glycosylation (termed GM viruses) (Ly and Stamatatos, 2000;
McCaffrey et al., 2004). GM viruses are named according to the
position of the N→Q mutation in the NXT/S motif using the
SF162 numbering system. A 10-fold difference in IC50 between
SF162 and each GM virus was considered significant.
Elimination of the conserved V3 loop glycan at position 299
within the N-terminal side of the V3 loop dramatically enhanced
the neutralization susceptibility of SF162 to the anti-V3 MAbs
(203-fold for P3C5 and over 20,000-fold for P3E1) while
deletion of the glycan at position 329 (immediately C-terminal
to the V3 loop) led to significant but somewhat less pronounced
enhancement in neutralization susceptibility (10.9-fold for
P3C5 and 120-fold for P3E1). In contrast, deletion of the
glycan at position 293 (immediately N-terminal to the V3 loop)
had a smaller effect on the susceptibility of SF162 to
neutralization by P3E1 and P3C5.
The glycan present at position 186 within the V2 loop also
had little, if any, role in protection of SF162 from the anti-V3
MAbs. The glycans in V1 (position 154) and C-terminal to the
V2 loop (position 195) played a more significant role,
particularly for MAb P3E1 (50-fold increase for position 154
and 10-fold increase for position 195). As previously reported
for the human anti-V3 MAbs 447-52D and 391-95 (Saunders et
al., 2005), the glycan at position 154 was more important for the
protection from anti-V3 MAbs than the glycan at position 195.
The glycans at positions 154 and 195 in V1V2 were also
involved in regulating the neutralizing potential of the anti-V1
MAbs discussed here (observed neutralization increases
between 10- and 250-fold) (Table 4). Furthermore, as we
described for anti-V3 MAbs, neutralization by all of the anti-V1
MAbs was enhanced strongly by deletion of the V3 glycan at
position 299 (ranging from 31- to 225-fold), somewhat less so
by deletion of the glycan at position 329 (ranging from 14- to
230-fold), and only slightly or not at all by deletion of the
glycan at position 293 (ranging from 1.4- to 3.5-fold). P1H6,
which is directed to an epitope slightly N-terminal to the
epitopes of the other 3 anti-V1 MAbs, was the only MAb which
neutralized the virus lacking the glycan at position 329 more
potently than the virus lacking the glycan at position 299,
suggesting that the former glycan may preferentially shield the
SSNWKE epitope over the WKEMDR epitope of V1.
We also examined whether glycans present in the V4–V5
region of Env, such as those at positions 382, 388, 392, 398,
401, 438, and 454 (McCaffrey et al., 2004), were involved in
modulating the neutralizing activities of the newly isolated
MAbs (Table 4). Our results indicate that these glycans have
only modest effects on the neutralizing potentials of the anti-V1
and anti-V3 MAbs and that these effects are strongest for the
glycans at positions 382 and 392. In these cases, removal of a
Table 2
Mouse monoclonal antibodies characterized in this study generated by immunization with gp140s
MAb Ig subclass Subunit Epitope Immunogen Immunization ELISA reactivity with Env antigens a Affinity (nM) determined by Biacore b
SF162
t-gp140 c
ΔV2
t-gp140
ΔV2
m-gp14
SF162
m-gp120
HxB2
gp41
SF162 t-gp140 ΔV2 t-gp140
ka
(×104)
kd
(×10−4)
KD
(nM)
ka
(×104)
kd
(×10−4)
KD
(nM)
P1H6 IgG1 κ gp120 V1 ΔV2gp140 DNA–Protein +++ d +++ +++ +++ − nd nd nd nd nd nd
P3C8 IgG1 κ gp120 V1 ΔV2gp140 Protein +++ +++ +++ +++ − nd nd nd nd nd nd
P3B2 IgG1 κ gp120 V1 ΔV2gp140 Protein +++ +++ +++ +++ − nd nd nd nd nd nd
P4D7 IgG1 κ gp120 V1 ΔV2gp140 Protein ++ ++ ++ ++ − nd nd nd nd nd nd
P3E1 IgG2α κ gp120 V3 SF162gp140 Protein +++ +++ +++ +++ − 25.60 0.73 0.29 12.90 0.76 0.59
P3C5 IgG2α κ gp120 V3 SF162gp140 DNA–Protein ++ ++ ++ ++ − nd nd nd nd nd nd
b12 IgG1 κ gp120 CD4BS HIV infection na e nd f nd nd nd nd 11.30 0.40 0.35 15.70 0.97 0.62
P1G9 IgG1 κ gp41 Cluster I SF162gp140 DNA–Protein + + − − ++ 1.13 1.62 14.30 8.26 1.79 21.67
P2D2 IgG2α κ gp41 C-HR ΔV2gp140 DNA–Protein ++ ++ − − ++ 2.01 3.00 14.90 2.12 3.38 15.94
P3G9 IgG2α κ gp41 Unknown SF162gp140 Protein + + − − ++ 2.15 3.14 14.60 1.64 3.59 21.89
P4A3 IgG2α κ gp41 Unknown SF162gp140 DNA–Protein +++ +++ − − +++ 7.12 0.94 1.30 4.70 0.95 2.02
P4C2 IgG1 κ gp41 Unknown SF162gp140 DNA–Protein ++ ++ − − ++ 4.50 1.35 3.00 2.74 2.23 8.14
2F5 IgG3 κ gp41 MPER HIV infection na nd nd nd nd nd 2.58 2.17 8.41 2.00 1.33 6.65
a Data reported are the average of two independent experiments.
b Values are the average of three independent experiments.
c ‘t’ indicates trimeric and ‘m’ indicates monomeric.
d ELISA half-maximal binding values (μg/ml) for Env proteins are denoted by + symbols. +++=0.001–0.01; ++=0.01–0.1; +=0.1–1.0; −=no binding.
e na indicates not applicable.
f nd indicates not determined in this study.
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Table 3
Neutralizing potential of MAbs
Isolate IC50 neutralization titer (μg/ml)
a
P1H6
(V1)
P3C8
(V1)
P3B2
(V1)
P4D7
(V1)
P3E1
(V3)
P3C5
(V3)
447-52D
(V3)
P1G9
(cluster I)
P2D2
(C-HR)
P3G9
(gp41)
P4A3
(gp41)
P4C2
(gp41)
2F5
(MPER)
SF162 0.3 0.6 1.0 0.8 0.2 16.0 0.2c – – – – – 1.0c
ΔV1 – b – – – 4.0 – 1c – – – – – 2.0c
ΔV2 0.003 0.003 0.01 0.08 b0.001 1.0 0.01c – – 25.0 – – b0.01c
ADA – – – – – – – – – – – – nd
ADA/SF162 V1 nd d nd nd nd – nd – nd nd nd nd nd nd
JRFL – – – – – – 15.0 – – – – – nd
JRFL/SF162 V1 nd nd nd nd 10 nd 1.5 nd nd nd nd nd nd
YU2 – – – – – – – – – – – – nd
YU2/SF162 V1 nd nd nd nd – nd 2.0 nd nd nd nd nd nd
HxB2 – – – – – – 0.2 – – – – – nd
HxB2/SF162 V1 nd nd nd nd – nd 0.01 nd nd nd nd nd nd
89.6 – – – – 6.0 – 0.001 – – – – – nd
89.6/SF162 V1 nd nd nd nd 0.1 nd b0.001 nd nd nd nd nd nd
SS1196.01 – – – – 3.5 – nd nd nd nd nd nd nd
6535.3 – – – – 16.5 – nd nd nd nd nd nd nd
7165.18 – – – – – – nd nd nd nd nd nd nd
6101.1 – – – – – – nd nd nd nd nd nd nd
QH0692.42 – – – – – – nd nd nd nd nd nd nd
QH0515.1 – – – – – – nd nd nd nd nd nd nd
AC10.0.29 – – – – – – nd nd nd nd nd nd nd
PVO.4 – – – – – – nd nd nd nd nd nd nd
TRO.11 – – – – – – nd nd nd nd nd nd nd
5768.4 – – – – – – nd nd nd nd nd nd nd
3988.25 – – – – – – nd nd nd nd nd nd nd
BG1168.1 – – – – – – nd nd nd nd nd nd nd
a Values reported are the average of 3 independent experiments.
b Indicates 50% neutralization not achieved at the highest MAb concentration tested, 25 μg/ml.
c Values are from Saunders et al. (2005).
d nd: not done.
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Overall, therefore, the neutralizing potentials of the anti-V1 and
anti-V3 MAbs were influenced by the presence of N-linked
glycosylation sites in both the V1V2 and V3 loops.
The anti-gp41 MAbs were unable to neutralize any of the
GM viruses studied here (data not shown).
Neutralization of heterologous isolates
To further examine the neutralization properties of the anti-
gp120 MAbs, we evaluated their abilities to neutralize hetero-
logous clade B HIV-1 isolates, including a lab-adapted isolate
(HxB2) and several well-characterized primary isolates from
both chronic and primary infection (Li et al., 2005) (Table 3).
Despite their potent neutralizing activities against SF162, the
V1-specific MAbs were not capable of neutralizing any of the
heterologous isolates tested. In fact, the only MAb with cross-
neutralizing activity was the anti-V3 MAb, P3E1, which
neutralized 89.6, SS1196.1, and 6535.3. The resistance of all
the other isolates to neutralization by P3E1 was not due to the
absence of the minimal P3E1 epitope, which was mapped to
IGPGRAF (see above) and which is present in many of the
isolates which were resistant to P3E1 neutralization (Li et al.,
2005; data not shown). Instead, the P3E1 epitope may be
shielded on these isolates by other regions of the viral Env, such
as the V1V2 loop (Krachmarov et al., 2006; Pinter et al., 2004;
Saunders et al., 2005). To test specifically whether or not the V1loops of heterologous isolates masked the P3E1 epitope, we
evaluated the ability of P3E1 to neutralize viruses expressing
chimeric Env constructed by replacing the V1 loop of each
isolate with that of SF162. We examined the neutralization of
such chimeras on the background of 89.6, JRFL, ADA, YU2,
and HxB2 in parallel with their wild type parent virus. As
control we used the well-characterized anti-V3 MAb, 447-52D
(Table 3). P3E1 was able to neutralize the chimeric 89.6/
SF162V1 and JRFL/SF162V1 viruses with significantly
enhanced potency compared to the corresponding wild type
viruses, indicating that on these two primary isolates, their V1
loop masks the exposure of the P3E1 epitope in V3.
Neutralization of the 89.6/SF162V1 and JRFL/SF162V1
chimeric viruses by 447-52D was also enhanced compared to
the wild type. However, 447-52D, but not P3E1, also
neutralized the chimeric YU2/SF162V1 and HxB2/SF162V1
viruses more efficiently than their wild type counterparts.
Affinity for soluble trimeric gp140 proteins by surface plasmon
resonance using Biacore
The neutralizing potential of anti-HIVMAbs has been linked
with their binding affinities for the HIV Env (Fouts et al., 1997).
However, the observed differences in the neutralizing potentials
of the anti-gp120 and anti-gp41 MAbs described here could not
be explained by their reactivities with trimeric gp140 by ELISA
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440 N.R. Derby et al. / Virology 366 (2007) 433–445(Fig. 1). We hypothesized that differences in the association or
dissociation rates of MAb-Env interactions could explain the
inability of the anti-gp41 MAbs to neutralize SF162. Thus, we
investigated the binding kinetics of the anti-gp41 MAbs with
soluble trimeric SF162gp140 and ΔV2gp140 proteins by
Biacore surface plasmon resonance (SPR). As controls for
these studies, we used the broadly neutralizing human MAbs
2F5 (anti-gp41) and b12 (anti-gp120), and the P3E1 mouse
MAb described here since it neutralized SF162 very potently
and displayed a modest breadth of neutralization.
Lack of neutralizing activity by the anti-gp41 MAbs could
not be attributed to either a slow association with or a rapid
dissociation from trimeric SF162gp140 as MAbs P4A3 and
P4C2 both had faster on rates and more stable off rates than the
human MAb 2F5 (Table 2), and yet only 2F5 neutralizes SF162
((Saunders et al., 2005) and Table 3). Furthermore, there was no
correlation between the ability of P3G9 to neutralize ΔV2, but
not SF162, and enhanced binding of this MAb to the trimeric
ΔV2gp140 protein over the trimeric SF162gp140 protein.
A difference in binding kinetics was observed, however,
when all anti-gp41 MAbs were compared with the two anti-
gp120 MAbs, P3E1 and b12, which neutralize SF162 very
efficiently (Table 3 and Binley et al., 2004; Saunders et al.,
2005). P3E1 and b12 had higher affinities for SF162gp140 and
ΔV2gp140 than any of the anti-gp41MAbs (Table 2). P3E1 and
b12 also bound with faster on rates and slower off rates than the
anti-gp41 MAbs. Differences in the kinetics of MAb binding to
soluble trimeric gp140 Env proteins, however, cannot explain
why b12 and 2F5 have a broader neutralizing potential than
P3E1. Breadth of neutralization may therefore be more directly
related to the accessibility of the epitope than with the kinetics
of binding to soluble gp140 proteins.
Discussion
In the present study, we describe the generation and
characterization of elevenMAbs elicited in response to immuniza-
tion with soluble trimeric SF162gp140 and ΔV2gp140 Env
immunogens. Our results suggest that there is a limited
repertoire of highly immunogenic regions on the gp120 portion
of our SF162-derived soluble trimeric gp140 proteins, namely:
the V1 and V3 loops. In contrast, a more diverse repertoire of
epitopes is recognized by the anti-gp41 MAbs elicited by these
immunogens. However, regardless of the epitopes they
recognize, all the anti-gp41 MAbs isolated here lacked
neutralizing activities. Because our gp140 immunogens are
soluble and not membrane-bound, regions of gp41 which are not
normally accessible on the virion-associated Env gp160 may
have elicited these anti-gp41 MAbs. The high immunogenicity
of regions of the gp41 ectodomain that are not accessible on
native virions may divert the ability of our gp140 constructs to
elicit NAbs. However, even if the anti-gp41 MAbs were able to
bind to the virion surface, the poor binding kinetics (slow on
rates and fast off rates) of many of these MAbs may hinder their
ability to neutralize. Interestingly, the binding of the anti-gp41
MAbs to their epitopes was greater in the context of the trimeric
gp140 than the monomeric gp140 while such a differential
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studies indicate that the binding properties of the anti-gp120 and
anti-gp41 antibodies elicited by our soluble trimeric gp140
immunogens differ significantly.
Although all the anti-gp120 MAbs displayed neutralizing
activity against SF162, only one MAb, the anti-V3 MAb P3E1,
displayed cross-neutralizing activity. P3E1 bound more effi-
ciently to its epitope (within the IGPGRAF V3 loop motif)
when the V3 loop was presented in the context of a protein
rather than as a peptide. Thus, P3E1-binding to IGPGRAF
appears to be affected by the conformational state of the V3
loop. Also, the ability of P3E1 to neutralize certain heterologous
isolates (such as JRFL and 89.6) improved when the V1 loops
from the Env of these isolates was replaced by that of SF162. A
similar observation was made for the broadly neutralizing anti-
V3 MAb 447-52D although this MAb was more potent in
neutralizing the chimeric viruses than P3E1. Therefore the
accessibility of the V3 loop to NAbs is affected by the nature of
the V1 loop. Since the V1 and V3 loops are not closely spaced
within the monomeric HIV Env (Chen et al., 2005; Kwong et
al., 1998), our results indicate that the V1 loop of one Env
protomer affects the exposure of V3 loop epitopes on an
adjoining Env protomer within the same trimeric spike.
Although P3E1 and 447-52D recognize overlapping epitopes,
the observation that 447-52D has a broader neutralizing activity
than P3E1 is most likely related to differences in the binding
constraints created by the positioning of the V1 loop on these
two MAbs. Our results indicate that in part these constraints are
imposed by the glycosylation pattern of the V1 loop. Additional
constraints are created, however, by the glycosylation pattern of
the V3 loop itself. Our results are in agreement with those of
others (Krachmarov et al., 2006; Pinter et al., 2004), indicating
that the V1V2 region influences the accessibility of anti-V3
NAbs, but our study highlights the important involvement of the
V1 loop itself in this regulation. Our observations strongly
suggest that improving the neutralizing potential of vaccine-
elicited anti-V3 MAbs will depend on our ability to overcome
several obstacles related to the positioning and glycosylation
pattern of the V1 loop.
An obvious question is why does the neutralizing ability of
anti-V3 MAbs (such as P3E1 or 447-52D (Saunders et al.,
2005)) not improve when the V1 loop is deleted from the SF162
Env (ΔV1 virus)? After all, deletion of the V2 loop renders HIV
more susceptible to neutralization by anti-V3 NAbs (Cao et al.,
1997; Saunders et al., 2005). Most likely, deletion of the V1 loop
results in the reorganization of many Env regions within each
protomer of the trimeric Env spike and these reorganizations do
not necessarily result in an enhanced exposure of the V3 loop. In
fact, they may result in its further occlusion. This is clearly
contrary to the way that the V2 loop affects the neutralizing
activity of anti-V3 NAbs. Our understanding of the interaction
between the V1, V2 and V3 loops will greatly improve when a
crystal structure of the entire trimeric Env containing the V1, V2,
and V3 variable loops becomes available.
Four out of the six anti-gp120 MAbs isolated so far
recognize the V1 loop. This observation suggests that the V1
loop is highly immunogenic on our gp140 immunogens andsupports results from immunogenicity studies conducted with
sera from SF162gp140-immunized macaques (Derby et al.,
2006). All four of the anti-V1 MAbs recognized the central
region of the V1 loop just C-terminal to the conserved SS
dipeptide, but N-terminal to the conserved GEIKNC motif. The
region of V1 just C-terminal to the SS dipeptide has previously
been identified as immunodominant on soluble trimeric YU2-
derived Env constructs (Li et al., 2006). We were unable to
examine whether the positioning of the V3 loop alters the
neutralizing properties of these anti-V1 MAbs, since deletion of
the V3 loop from the SF162 Env abrogates its fusogenic
potential (Saunders et al., 2005), but their binding was not
abrogated by the absence of the V3 loop from the SF162 Env
(data not shown). Clearly their neutralizing potential was
affected by the V2 loop and the glycosylation patterns of the
V1V2 and V3 regions. We have not yet determined whether
deletion of the V2 loop and elimination of N-linked glycosyla-
tion sites from heterologous Env will improve the cross-
neutralizing potentials of these anti-V1 MAbs. However, in
contrast to the observations made with the anti-V3 MAb P3E1,
we do not believe that the absence of cross-neutralizing activity
of the anti-V1 MAbs is related to the occlusion of their epitopes
on heterologous Envs, but rather to the fact that their epitopes
are highly variable among HIV isolates.
Our studies contribute to the understanding of the immuno-
genic properties of currently evaluated gp140 Env immuno-
gens, and they provide additional information on the interaction
of gp140-elicited antibodies with homologous and heterologous
isolates. They highlight that the limitation of soluble HIV Env
gp140 immunogens to elicit robust cross-reactive neutralizing
antibody responses is not only due to the elicitation of high titers
of homologous antibodies, but also to the elicitation of
significant titers of antibodies whose epitopes although exposed
on these immunogens, are naturally occluded, or not present, on
the virion-associated Env. Such information could be used to
improve the ability of gp140 immunogens to elicit cross-
reactive neutralizing antibody responses.
Materials and methods
Monoclonal antibodies
Eleven mouse MAbs were generated and characterized in
this study. The human MAbs, IgG1b12 (Burton et al., 1994),
directed to the CD4 binding site, and 2F5 (Zwick et al., 2001),
directed to the MPER of gp41, were obtained from the NIH
AIDS Research and Reference Reagent Program (ARRRP).
MAb 447-52D (Conley et al., 1994; Gorny et al., 1992, 1993),
directed to the GPGR motif at the crown of the V3 loop of
gp120, and MAb 1418 (Conley et al., 1994; Gorny et al., 1992,
1993), directed to the parvovirus glycoprotein, were provided
by Susan Zolla-Pazner and Mirek Gorny (New York University,
New York, NY). MAb 17b (Sullivan et al., 1993), directed to a
CD4-induced (CD4i) epitope, was provided by James Robinson
(Tulane University, New Orleans, LA) and IgG X5 (Moulard et
al., 2002), directed to a different CD4i epitope, was provided by
Dimiter Dimitrov (National Cancer Institute, Frederick, MD).
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CHO-produced recombinant Env proteins: monomeric
SF162gp120, trimeric SF162gp140, trimeric ΔV2gp140,
monomeric ΔV2gp140, monomeric US4gp140 (clade B),
monomeric SF2gp120 (clade B), trimeric TV1gp140 (clade
C), trimeric MJ4gp140 (clade C), and four domain soluble CD4
(sCD4) were provided by Novartis Vaccine and Diagnostics
(Emeryville, CA) (Srivastava et al., 2003a). P. pastoris
produced recombinant gp41 ectodomain lacking the fusion
peptide, membrane-spanning, and cytoplasmic domains (aa
541–682) from the HxB2 isolate (HxB2gp41) was purchased
from Viral Therapeutics (Ithaca, NY).
Chimeric proteins expressing the V1V2 region of SF162 Env
(V1V2-CP), or the V3 region of JR-CSF Env (V3-CP) on the
MLV envelope glycoprotein gp70 background (Kayman et al.,
1994) were provided by Abraham Pinter (Public Health
Research Institute, Newark, NJ).
Peptides derived from the V1 and V2 variable regions of
SF162 Env were purchased from Sigma-Genosys (The Wood-
lands, TX). An SF162 V3 peptide was provided by Novartis.
Peptides spanning the V1 and V3 regions of the HIV-1 clade B
consensus Env sequence (Catalog #9480) and the SHIVSF162P3
Env sequence (Catalog #7619) were obtained from the ARRRP.
V3 peptides from HIV-1 MN (Catalog #6451) were also
obtained from the ARRRP. Two gp41 peptides spanning the
epitopes of 2F5 and 4E10 were provided by John Mascola and
Richard Wyatt (VRC/NIH, Bethesda, MD), and a set of 43
overlapping peptides encompassing the entire gp41 ectodomain
derived from the SHIVSF162P3 gp41 Env was obtained from the
ARRRP (Catalog # 7619). The sequences of all above-
mentioned peptides are reported in Table 1.
Mice and immunizations
8- to 12-week-old RBF/DnJ mice were immunized as
follows. Mouse 1L was immunized with the recombinant
trimeric SF162gp140 protein; mouse 1R was immunized
with the recombinant trimeric ΔV2gp140 protein; mouse 2L
was immunized with a DNA vector expressing SF162gp140
and subsequently with the recombinant trimeric SF162gp140
protein as a boost; and mouse 2R was immunized with a
DNA vector expressing ΔV2gp140 and subsequently with
the recombinant trimeric ΔV2gp140 protein as a boost. The
construction and characterization of SF162gp140 and
ΔV2gp140 plasmid DNA and recombinant proteins has
been described extensively elsewhere (Barnett et al., 2001;
Srivastava et al., 2003a; Stamatatos et al., 2000). Mouse 1L
received 11 immunizations with recombinant SF162gp140
(5–50 μg). During the 1st, 2nd and 9th immunizations, the
protein was mixed with Ribi adjuvant. No adjuvant was
used during the remaining immunizations. Mouse 1R was
immunized 13 times with recombinant ΔV2gp140 (5–
50 μg). Ribi adjuvant was used during the 1st, 2nd, 9th
and 12th immunizations. Mouse 2L was immunized twice
with a DNA vector expressing SF162gp140 and subse-
quently 8 times with the recombinant trimeric SF162gp140protein. Mouse 2R was immunized twice with a DNA vector
expressing ΔV2gp140 and subsequently 9 times with the
recombinant trimeric ΔV2gp140 protein. For mice 2L and
2R, Ribi adjuvant was used during both DNA immuniza-
tions and during the first immunization with recombinant
protein. No adjuvant was used during the remaining protein
immunizations.
Hybridomas and monoclonal antibodies
Serawere collected throughout the immunization schedule and
monitored for the presence of anti-Env antibodies. Three days
following the final immunization, the mice were euthanized and
their spleens were harvested. Splenocytes were fused with a
myeloma cell line. Splenocytes were fused with FOX NY
myeloma cells to generate hybridomas secreting anti-HIV Env
antibody. Between 20 and 30 hybridoma supernatants were
screened for reactivity with HIV Env proteins by ELISA. The
soluble protein antigens used for ELISA screening were
SF162gp140, SF162gp120, US4gp140, SF2gp120, HxB2gp41,
TV1gp140, and MJ4gp140. Two to four hybridomas displaying
the broadest cross-reactivity by ELISA were selected for further
characterization.
Selected hybridomas were cloned by limiting dilution, and
the secreted antibodies were purified on protein A/G agarose
columns (Pierce, Rockford, IL) according to the manufac-
turer's instructions and as previously described (Derby et al.,
2006). Briefly, hybridoma supernatants were concentrated by
centrifugation using Centricon-80 30 kDa cut-off filters, and
the concentrate was diluted in binding buffer pH 8.0 (Pierce)
and applied to pre-equilibrated protein A/G agarose columns.
Columns were washed with binding buffer, and bound IgG
was eluted with imidazole, pH 2.0 (Pierce). Those fractions
containing the highest concentrations of protein (by UV
absorbance at 280 nm) that reacted with SF162gp140 by
ELISA were pooled, buffer-exchanged in PBS to remove
elution buffer salts, concentrated, and sterile-filtered. The
concentration of the final product was determined by UV
absorbance at 280 nm and adjusted to 2 mg/ml in PBS.
MAb-epitope specificity and affinity determination by ELISA
MAbs were serially diluted into microtiter ELISA plates
(Immulon 2HB, Thermo electron, Waltham, MA), which had
been coated overnight with one of the following proteins (50 ng/
well): gp140, gp120, gp41, V1V2-CP, or V3-CP; or with Env-
derived peptides (100 ng/well), and MAb binding was
determined as previously described (Barnett et al., 2001;
Srivastava et al., 2003b; Xu et al., 2006). Half-maximal MAb
binding titers were determined as the μg/ml concentration of
MAb at which the OD490 was half that at saturation.
Biacore surface plasmon resonance
Surface plasmon resonance studies were performed on either
a Biacore X or Biacore 3000 (Biacore, Uppsala, Sweden) using
Biacore 3000 Control Software (Biacore). Approximately
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anti-mouse IgG (Biorad, Hercules, CA) or goat–anti-human
IgG (Biorad), were immobilized on CM5 chips (Biacore) by
standard amine coupling according to the manufacturer's
instructions. For kinetic analysis, approximately 400 RU of
each MAb were then captured onto the surface. Soluble trimeric
SF162gp140 or ΔV2gp140 proteins in HBS–EP buffer
(Biacore) were then injected over the MAbs in a concentration
series ranging from 500 nM to 1.56 nM in 2-fold serial
dilutions. Kinetic injections were performed for 3 min at a flow
rate of 20 μl/min followed by 60 min of dissociation. Between
protein injections, chips were regenerated down to the goat–
anti-mouse or goat–anti-human IgG surface by 10-s injections
of glycine pH 1.5 buffer at a flow rate of 100 μl/min. All assays
were performed in triplicate, and the data were analyzed using
the Biaevaluation 3.1 Software (Biacore) and fitted according to
a Langmuir 1:1 with or without drifting baseline model.
Viruses
Single round competent viruses
Luciferase reporter viruses capable of only a single round of
replication were generated in HEK 293T cells as previously
described (McCaffrey et al., 2004; Saunders et al., 2005). In
most cases, viruses were concentrated by centrifugation at
3000 rpm through an Amicon Ultra-15 100-kDa cut-off filter
(Millipore) to enhance their infectious titers. Single round
competent viruses expressing Env proteins from the following
isolates were generated: SF162, variable loop-deleted variants
of SF162 (ΔV1 lacking the V1 loop and ΔV2 lacking the V2
loop) (Saunders et al., 2005), and SF162 variants lacking
specific N-linked glycosylation sites around the V3 loop
(GM293, GM299, GM329), the V4 loop (GM382, GM388,
GM392, GM398, GM401), and the C4V5 region (GM438,
GM454) (McCaffrey et al., 2004). Single round competent
viruses were also generated that expressed heterologous Env
proteins: HxB2 (a Tcell line-adapted clade B virus); 89.6, ADA,
JRFL, and YU2 (clade B primary isolates from chronic
infection); and 3988.25, 5768.4, 6101.1, 6535.3, 7165.18,
AC10.0.29, BG1168.1, QH0515.1, QH0692.42, PVO.4,
SS1196.1, TRO.11, REJO4541.67, and RHPA4259.67 (clade
B primary isolates collected within 3 months following HIV
infection) (Li et al., 2005).
Replication competent viruses
In some experiments, replication competent SF162, GM154,
GM186 and GM195 viruses were used. The generation of such
viruses was previously reported (Ly and Stamatatos, 2000).
HIV Neutralization assays
Neutralization assays were performed in TZM-bl cells as
previously described (Derby et al., 2006). Percent neutralization
at each MAb concentration was calculated based on the
reduction in virus entry determined from the reduction in cell-
associated luciferase (relative light units, RLU) in the presence
of MAb relative to the entry in the absence of MAb as describedmathematically here: [(RLUcells + virus−RLUcells + virus +MAb) /
RLUcells + virus]×100.
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